Table 2 Base-case probabilities and sensitivity analysis parameter estimates
Parameters | High risk [sensitivity estimates] | Moderate risk [sensitivity estimates] |
---|---|---|
Mutation prevalence | 18% (Stoppa-Lyonnet et al, 1997) [7% (Couch et al, 1997; Stoppa-Lyonnet et al, 1997), 27% (Eccles et al, 1998)] | |
Mutation penetrance | BRCA1/2 | 25%a [17%, 33%]c |
82% (Easton et al, 1993) [70%a, 82%] | ||
Unidentified mutation | ||
40%a [35%, 40%]a | ||
Prophylactic mastectomy | 5%c [5%c, 38%d] | 0%c |
Prophylactic oophorectomy | 5%c [0%c, 14%d] | 0%c |
Prophylactic mastectomy and oophorectomy | 5%c [0%c, 13%d] | 0%c |
5 year death rate for genetics service patients | 35 – 54 years 7.8% – 2 year lead time [3.8% with no lead time, 9.4% with a 2 year lead time]b | 35–54 years 7.8% – 2 year lead time [3.8% with no lead time, 9.4% with a 2 year lead time]b |
55 – 59 years 11.5% – 2 year lead time [6.9% with no lead time, 16.7% with a 2 year lead time]b | 55 – 59 years 11.5%-2 year lead time [6.9% with no lead time, 16.7% with a 2 year lead time]b | |
5 year death rate for nongenetics service patients | 35 – 54 years 28.4%b [24.4%, 35.1%) – no lead timeb | 35–54 years 28.4%b [24.4%, 35.1%] – no lead timeb |
55 – 59 years 34.9% [30.2%, 39.0%] – no lead timeb | 55 – 59 years 34.9% [30.2%, 39.0%] – no lead timeb | |
Number of Markov cycles/years | 24 [15, 24] | 19 [9, 19] |